Drug Profile


Alternative Names: MTBVAC 01

Latest Information Update: 09 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biofabri; University of Zaragoza
  • Developer Biofabri
  • Class Attenuated vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Tuberculosis

Most Recent Events

  • 24 May 2018 Biofabri and University of Zaragoza plan a phase IIa trial for Tuberculosis (Prevention) in South Africa (Parenteral), in July 2018 (NCT03536117)
  • 01 Mar 2018 Biofabri completes a phase I/II trial in Tuberculosis (Prevention) in South Africa (NCT02729571)
  • 12 Oct 2016 Aeras, Biofabri, the University of Zaragoza and the South African Tuberculosis Vaccine Initiative plan a phase Ib/IIa trial for Tuberculosis (Prevention, In adults) in USA and South Africa (Intradermal, Injection) (NCT02933281)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top